PHAT - Phathom Pharmaceuticals - Stock Price & Catalysts • BiopharmIQ

Enterprise Value

590.7M

Cash

129.6M

Avg Qtr Burn

-35.36M

Short % of Float

17.48%

Insider Ownership

21.52%

Institutional Own.

70.57%

Qtr Updated

03/31/23

Drug Pipeline

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
VOQUEZNA (Vonoprazan) (Potassium competitive acid blocker) Details Bacterial infection	Approved Quarterly sales	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Vonoprazan (Potassium competitive acid blocker) Details Intestinal infection, Esophagitis, Gastroesophageal reflux disease	NDA Acceptance for review	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Vonoprazan (Potassium competitive acid blocker) Details Intestinal infection	Phase 3 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.